Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 273 for

Edit search filters
  1. Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects with Chronic HCV with Advanced Liver Disease or Post-Liver Transplant

    Jacksonville, FL

  2. Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in Treatment-Naïve HCV Genotype 1-Infected Adults With Chronic Kidney Disease

    Scottsdale/Phoenix, AZ

  3. Acupuncture Therapy for COVID-Related Olfactory Loss

    Rochester, MN

  4. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (enrollment by invitation only)

    Rochester, MN

  5. An Expanded Access Study of Sofosbuvir Combined with Ribavirin and Either with or without Pegylated Interferon for Treating Aggressive Post-Transplant Hepatitis C

    Jacksonville, FL

  6. Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients

    Rochester, MN

  7. A Study to Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (CDI)

    Rochester, MN

  8. Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

    Rochester, MN

  9. ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

    Rochester, MN

  10. Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

    Rochester, MN

.

Mayo Clinic Footer